A share price of Adicet Bio Inc [ACET] is currently trading at $2.35, up 0.86%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ACET shares have gain 15.20% over the last week, with a monthly amount glided 0.86%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, March 2024, Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4). In a post published today on Yahoo Finance, Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024.
From an analyst’s perspective:
Adicet Bio Inc [NASDAQ: ACET] stock has seen the most recent analyst activity on June 27, 2023, when JMP Securities downgraded its rating to a Mkt Perform. Previously, Guggenheim downgraded its rating to Neutral on June 27, 2023. On June 01, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $6 on the stock. JP Morgan started tracking the stock assigning a Overweight rating and suggested a price target of $23 on September 21, 2022. SMBC Nikko initiated its recommendation with a Outperform and recommended $28 as its price target on March 31, 2022. Truist started tracking with a Buy rating for this stock on March 08, 2022, and assigned it a price target of $30. In a note dated March 04, 2022, Jefferies initiated an Buy rating and provided a target price of $27 on this stock.
Adicet Bio Inc experienced fluctuations in its stock price throughout the past year between $1.10 and $7.50. Currently, Wall Street analysts expect the stock to reach $32.5 within the next 12 months. Adicet Bio Inc [NASDAQ: ACET] shares were valued at $2.35 at the most recent close of the market. An investor can expect a potential return of 1282.98% based on the average ACET price forecast.
Analyzing the ACET fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 6.08%, Pretax Profit Margin comes in at 5.72%, and Net Profit Margin reading is 5.6%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is 7.63 and Total Capital is -0.71. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.31 points at the first support level, and at 2.27 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.39, and for the 2nd resistance point, it is at 2.44.
Adicet Bio Inc [ACET] reported earnings per share of -$0.69 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.69/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.16 per share as compared to estimates of -$0.74 per share, a difference of -$0.42 representing a surprise of -56.80%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Adicet Bio Inc [NASDAQ:ACET] is 8.41. As well, the Quick Ratio is 8.41, while the Cash Ratio is 9.27.
Transactions by insiders
Recent insider trading involved ORBIMED ADVISORS LLC, Director, that happened on Jan 25 ’24 when 3.12 million shares were purchased. Director, GORDON CARL L completed a deal on Jan 25 ’24 to buy 3.12 million shares. Meanwhile, President & CEO Schor Chen bought 5500.0 shares on Oct 02 ’23.
